GlassScriptPhysician profile
Cheryl A Cavalli
NPI 1306841325
$4,634.23
in general payments reported to CMS, 2019-2025
28 companies · $590 in 2025
The $590 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $747 · 2020: $480 · 2021: $733 · 2022: $549 · 2023: $977 · 2024: $557 · 2025: $590.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,123.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $974.84 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $878.98 | 2019-2025 | Wegovy, Ozempic |
| Janssen Pharmaceuticals, INC | $593.88 | 2019-2024 | Xarelto |
| Pfizer INC. | $565.52 | 2021-2025 | |
| Glaxosmithkline, LLC. | $542.33 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Astrazeneca Pharmaceuticals LP | $138.41 | 2021-2024 | Breztri, Farxiga |
| Boston Scientific Corporation | $124.41 | 2023 | Watchman Access System |
| Janssen Scientific Affairs, LLC | $106.73 | 2025 | Spravato |
| Astellas Pharma US INC | $92.25 | 2020-2023 | Veozah |
| Idorsia Pharmaceuticals US INC | $90.08 | 2022-2023 | Quviviq |
| Eisai INC. | $89.34 | 2020-2022 | |
| Viatris Specialty LLC | $48.07 | 2025 | Yupelri |
| Dexcom, INC. | $47.47 | 2023-2024 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $36.81 | 2022-2024 | Caplyta |
| Novartis Pharmaceuticals Corporation | $36.50 | 2022-2023 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $33.76 | 2020 | |
| Lilly USA, LLC | $33.44 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $30.39 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.96 | 2020-2024 | Xifaxan |
| Aimmune Therapeutics, INC. | $21.56 | 2025 | Zenpep |
| Axsome Therapeutics, INC. | $17.63 | 2025 | Symbravo |
| Takeda Pharmaceuticals U.S.A., INC. | $16.21 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.80 | 2022 | |
| Seqirus USA INC | $15.48 | 2024 | Fluad, Flucelvax |
| Merck Sharp & Dohme LLC | $15.41 | 2022 | |
| Avion Pharmaceuticals | $14.38 | 2019 | |
| Shire North American Group INC | $13.22 | 2019 | |
| Amgen INC. | $11.37 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheryl Cavalli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.